The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Plus Therapeutics’ injectable radiotherapy, Rhenium (186 Re) Obisbemeda, for treating leptomeningeal ...

New�Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups� �Data on Health Status Improvements Over Time Following Culture ...

Liquidia Corporation announced its financial results for the year ending December 31, 2024, highlighting a strengthened financial position with up to $100 million available through an amended ...

Wanbury Limited, a pharmaceutical company listed on both NSE and BSE, announced today it will launch two new products this ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory ... Liquidia continues to progress clinical studies of L606 (liposomal treprostinil) inhalation suspension, an investigational ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...

Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) ...